Molecular Evidence Development Consortium
EIN: 472986038 · Rexburg, ID
| Metric | Value |
|---|---|
| Total Expenses | $431K |
| Net Assets | $932K |
Is Molecular Evidence Development Consortium Legit?
Insufficient Data
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
About Molecular Evidence Development Consortium
Molecular Evidence Development Consortium (EIN: 472986038) is a nonprofit organization based in Rexburg, ID. The organization reported total revenue of $0 and total assets of $0 according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Molecular Evidence Development Consortium's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Molecular Evidence Development Consortium is a small nonprofit, with 2 years of IRS 990 filings on record (2015–2016). Revenue has grown at a compound annual rate of 53.3%.
Key Financial Metrics (2016)
From the most recent IRS 990 filing on record:
| Total Revenue | $950K |
| Total Expenses | $431K |
| Surplus / Deficit | +$519K |
| Total Assets | $995K |
| Total Liabilities | $63K |
| Net Assets | $932K |
| Operating Margin | 54.6% |
| Debt-to-Asset Ratio | 6.3% |
| Months of Reserves | 27.7 months |
Financial Health Grade: A
In 2016, Molecular Evidence Development Consortium reported a surplus of $519K with revenue exceeding expenses, holds 27.7 months of operating reserves (strong position), has a debt-to-asset ratio of 6.3% (very low leverage).
Financial Trends
Over 2 years of filings (2015–2016), Molecular Evidence Development Consortium's revenue has grown at a compound annual growth rate (CAGR) of 53.3%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2016 | +53.3% | +161.5% | +117.8% |
AI Analysis Pending
AI enrichment for Molecular Evidence Development Consortium has not yet been completed. Basic IRS 990 data is shown below. Check back later for a full transparency report including a Mission Score, spending breakdown, executive compensation analysis, and red flags assessment.
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Molecular Evidence Development Consortium with a Mission Score of 0 out of 100 (Very Poor). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Key Financial Metrics (2016)
From the most recent IRS 990 filing on record:
- The organization reported a surplus of $519K, with revenue exceeding expenses.
- Debt-to-asset ratio: 6.3%.
Frequently Asked Questions about Molecular Evidence Development Consortium
Is Molecular Evidence Development Consortium a legitimate charity?
Molecular Evidence Development Consortium (EIN: 472986038) is a registered tax-exempt nonprofit based in Idaho. It has 2 years of IRS 990 filings on record. No red flags identified. Financial health grade: A.
How does Molecular Evidence Development Consortium spend its money?
Molecular Evidence Development Consortium reported its financials in IRS 990 filings. 2 years of filing data available. Revenue exceeded expenses in the most recent year. Review the full spending breakdown on NonprofitSpending.
Are donations to Molecular Evidence Development Consortium tax-deductible?
Molecular Evidence Development Consortium is registered as a tax-exempt nonprofit (EIN: 472986038). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
Where is Molecular Evidence Development Consortium located?
Molecular Evidence Development Consortium is headquartered in Rexburg, Idaho and files with the IRS under EIN 472986038.
How many years of IRS 990 filings does Molecular Evidence Development Consortium have?
Molecular Evidence Development Consortium has 2 years of IRS 990 filings on record at NonprofitSpending. Additional filing years may become available as the IRS releases new data.
Filing History
IRS 990 filing history for Molecular Evidence Development Consortium showing financial trends over 2 years of public records:
Over 2 years of IRS 990 filings (2015–2016), Molecular Evidence Development Consortium's revenue has grown by 53.3%, moving from $620K to $950K. Total assets increased by 117.8% over the same period, from $457K to $995K. Total functional expenses rose by 161.5%, from $165K to $431K. In its most recent filing year (2016), Molecular Evidence Development Consortium reported a surplus of $519K, with revenue exceeding expenses. The organization holds $63K in liabilities against $995K in assets (debt-to-asset ratio: 6.3%), resulting in net assets of $932K.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2016 | $950K | $431K | $995K | $63K | — | View 990 |
| 2015 | $620K | $165K | $457K | $2K | — | View 990 |
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Molecular Evidence Development Consortium:
Data Sources and Methodology
This transparency report for Molecular Evidence Development Consortium is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.